Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigtion of development of the 'serotonin syndrome'

Clinical Pharmacology and Therapeutics

Volumn 63, Issue 4, 1998, Pages 403-413

  Dingemanse, Jasper ^a   Wallnöfer, Andreas ^b   Gieschke, Ronald ^b   Guentert, Theodor ^b   Amrein, Roman ^b  

^a Jacor Research   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; FLUOXETINE; MOCLOBEMIDE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONCENTRATION LOSS; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INSOMNIA; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SEROTONIN SYNDROME; VERTIGO; VOLUNTEER; VOMITING;

3,4-DIHYDROXYPHENYLACETIC ACID; ADULT; ANTIDEPRESSIVE AGENTS; BENZAMIDES; BLOOD PLATELETS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HUMANS; HYDROXYINDOLEACETIC ACID; MALE; METHOXYHYDROXYPHENYLGLYCOL; MOCLOBEMIDE; REFERENCE VALUES; SEROTONIN UPTAKE INHIBITORS; SYNDROME;

EID: 0031901578     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90035-2     Document Type: Article

References (45)

1. White K, Simpson G. Combined MAOI-tricyclic antidepressant treatment: a reevaluation. J Clin Psychopharmacol 1981;1:264-82.
2. Feighner JP, Boyer WF, Tyler DL, Neborsky RJ. Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry 1990;51:222-5.
3. Miller F, Freidman R, Tanenbaum J, Griffin A. Disseminated intravascular coagulation and acute myoglobinuric renal failure: a consequence of the serotonergic syndrome. J Clin Psychopharmacol 1991;11:277-9.
4. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;14:705-13.
5. Fitton A, Faulds D, Goa KL. Moclobemide: an update of its pharmacological properties and therapeutic use. Drugs 1996;52:450-74.
6. Amrein R, Guentert TW, Dingemanse J, Lorscheid T, Stabl M, Schmid-Burgk W. Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies. Psychopharmacology 1992;106:S24-31.
7. Marley E, Wozniak KM. Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine reuptake inhibitors. Psychol Med 1983; 13:735-49.
8. Marley E, Wozniak KM. Interactions between relatively selective monoamine oxidase inhibitors and an inhibitor of 5-hydroxytryptamine reuptake, clomipramine. J Psychiatr Res 1985;19:597-608.
9. Sleight AJ, Marsden CA, Martin KF, Palfreyman MG. Relationship between extracellular 5-hydroxytryptamine and behaviour following monoamine oxidase inhibition and L-tryptophan. Br J Pharmacol 1988;93:303-10.
10. Bonetti EP, Scherschlicht R, Da Prada M. Safety of the RIMA antidepressant moclobemide: minimal interactions with dietary tyramine and 5-HT uptake blockers. In: Racagni G, Fukuda T, Brunello N, editors. Biological Psychiatry; vol 29 (11S). Amsterdam: Elsevier Science Publishers BV; 1991; p. 390-2.
11. Wallnöfer A, Guentert TW, Eckernäs SA, Dingemanse J. Moclobemide and fluvoxamine co-administration: a prospective study in healthy volunteers to investigate the potential development of the "serotonin syndrome." Hum Psychopharmacol 1995;10:25-31.
12. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996;31:444-69.
13. Fulton B, McTavish D. Fluoxetine: an overview of its pharmacodynamic and pharmacokinetic properties and review of its therapeutic efficacy in obsessive-compulsive disorder. CNS Drags 1995;3:305-22.
14. Messiha FS. Fluoxetine: adverse effects and drug-drug interactions. Clin Toxicol 1993;31:603-30.
15. Mortimer O, Lindstrom B, Laurell H, Bergman U, Rane A. Dextromethorphan: polymorphic serum pattern of the O-demethylated and didemethylated metabolites in man. Br J Clin Pharmacol 1989;27:223-7.
16. Bergstrom RF, Lemberger L, Fand NA, Wolen RL. Clinical pharmacology and pharmacokinetics of fluoxetine: a review. Br J Psychiatry 1988;153:47-50.
17. Jauch R, Griesser E, Oesterhelt G, Arnold W, Meister W, Ziegler WH, et al. Biotransformation of moclobemide in humans. Acta Psychiatr Scand Suppl 1990;360:87-90.
18. Geschke R, Koerner J, Eggers H. Determination of the new monoamine oxidase inhibitor moclobemide and three of its metabolites in biological fluids by HPLC. J Chromatogr 1987;420:111-20.
19. Orsulak PJ, Kenney JT, Debus JR, Crowley G, Wittman PD. Determination of the antidepressant fluoxetine and its metabolite norfluoxetine in serum by reversed-phase HPLC with ultraviolet detection. Clin Chem 1988; 34:1875-8.
20. Koulu M, Scheinin M, Kaarttinen A, Kallio J, Pyykkö K, Vuorinen J, et al. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. Br J Clin Pharmacol 1989;27:243-55.
21. Minegishi A, Ishizaki T. Rapid and simple method for the simultaneous determination of 3,4-dihydroxyphenylacetic acid, 5-HIAA and 4-hydroxyphenylacetic acid in human plasma, by HPLC with electrochemical detection. J Chromatogr 1984;308:55-63.
22. Ross SB, Aperia B, Beck-Friis J, Jansa S, Wetterberg L, Åberg A. Inhibition of 5-hydroxytryptamine uptake in human platelets by antidepressant agents in vivo. Psychopharmacology 1980;67:1-7.
23. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker; 1982.
24. Dingemanse J, Kneer J, Wallnöfer A, Kettler R, Zürcher G, Koulu M, et al. Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline. Clin Neuropharmacol 1996;19:399-414.
25. Cooper GL. The safety of fluoxetine - an update. Br J Psychiatry 1988;153:77-86.
26. Versiani M, Nardi E, Figueira IL, Stabl M. Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo. Acta Psychiatr Scand Suppl 1990;360:24-8.
27. Chen D, Ruch R. Safety of moclobemide in clinical use. Clin Neuropharmacol 1993;16:63-8.
28. van Oefele K, Grohmann R, Hippius H, Rüther E. Unerwünschte Arzneimittelwirkungen bei der Kombinationsbehandlung mit trizyklischen Antidepressiva und Monoaminooxidase-Hemmern. Nervenarzt 1988; 59:118-23.
29. Bakish D, Hooper CL, West DL, Miller C, Blanchard A, Bashir F. Moclobemide and specific serotonin reuptake inhibitor combination treatment of resistant anxiety and depressive disorders. Hum Psychopharmacol 1995; 10:105-9.
30. Joffe RT, Bakish D. Combined SSRI-moclobemide treatment of psychiatric illness. J Clin Psychiatry 1994;55:24-5.
31. Ebert D, Albert R, May A, Stosiek I, Kashka W. Combined SSRI-RIMA treatment in refractory depression: safety data and efficacy. Psychopharmacology 1995; 119:342-4.
32. Hawley CJ, Ratnam S, Pattinson HA, Quick SJ, Echlin D. Safety and tolerability of combined treatment with moclobemide and SSRIs: a preliminary study of 19 patients. J Psychopharmacol 1996;10:241-5.
33. Lemberger L, Bergstrom RF, Wolen RL, Farid NA, Eras GG, Aronoff GR. Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry 1985;46:14-9.
34. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-20.
35. Gram LF, Guentert TW, Grange S, Vistisen K, Brosen K. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther 1995;57:670-7.
36. Mayersohn M, Guentert TW. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacokinet 1995;29:292-332.
37. Brøsen K, Skjelbo E. Fluoxetine and norfluoxetine are potent inhibitors of P450 IID6 - the source of the sparteine/debrisoquine oxidation polymorphism. Br J Clin Pharmacol 1991;32:136-7.
38. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34:262-5.
39. Guentert TW, Grange S, Bock J, Waldburger R, Birnboeck H. Lack of an important influence of CYP2D6 oxidation status on the pharmacokinetics of moclobemide [abstract]. Clin Pharmacol Ther 1995;57:151.
40. Schoerlin MP, Blouin RA, Pfefen JP, Guentert TW. Comparison of the pharmacokinetics of moclobemide in poor and efficient metabolizers of debrisoquine. Acta Psychiatr Scand Suppl 1990;360:98-100.
41. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993;53:401-9.
42. Dingemanse J, Wood N, Guentert T, Øic S, Ouwerkerk M, Amrein R. Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects. Psychopharmacology [in press].
43. Dingemanse J, Korn A, Pfefen JP, Guentert TW. Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations. Psychopharmacology 1992;106:S46-8.
44. Benfield P, Heel RC, Lewis SP. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986;32:481-508.
45. Davis BA, Kennedy SH, Durden DA, D'Souza J, Goldbloom DS, Boulton AA. The effect of the MAO-A selective inhibitor brofaromine on the plasma and urine concentrations of some biogenic amines and their acidic metabolites in bulimia nervosa. Prog Neuropsychopharmacol Biol Psychiatry 1993;17:747-63.